Back to Search
Start Over
Circulating adipose-tissue miRNAs in gastrointestinal cancer patients and their association with the level and type of adiposity at body composition analysis.
- Source :
-
Frontiers in molecular biosciences [Front Mol Biosci] 2024 Jul 30; Vol. 11, pp. 1449197. Date of Electronic Publication: 2024 Jul 30 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: Adipose tissue (AT) wasting in cancer is an early catabolic event with negative impact on outcomes. Circulating miRNAs may promote body weight loss and cachexia. We measured circulating miRNAs linked to AT alterations and compared their levels between i) gastrointestinal (GI) cancer patients and controls, ii) cachectic and non-cachectic cancer patients, and iii) according to adiposity level and its distribution.<br />Methods: Patients with GI cancer and subjects with benign diseases as controls were considered. Cachexia was assessed and adiposity evaluated by CT-scan for subcutaneous AT area (SAT), visceral AT area and the total AT area (TAT). MiRNAs involved were measured in plasma by RT-qPCR.<br />Results: 37 naïve GI cancer patients and 14 controls were enrolled. Patients with cachexia presented with lower SAT compared to non-cachectic ( p < 0.05). In cancer patients, we found higher levels of miR-26a, miR-128, miR-155 and miR-181a vs. controls ( p < 0.05). Cancer patients with BMI < 25 kg/m <superscript>2</superscript> showed higher levels of miR-26a vs. those with BMI ≥ 25 ( p = 0.035). MiR-26a and miR-181a were higher in cachectic and non-cachectic vs. controls ( p < 0.05). Differences between cachectic and controls were confirmed for miR-155 ( p < 0.001) but not between non-cachectic vs. control ( p = 0.072). MiR-155 was higher in cachectic patients with low TAT vs. those without cachexia and high TAT ( p = 0.036).<br />Conclusion: Our data confirm a modulation of specific and different miRNAs involved in AT metabolism in cancer and cachexia. MiR-155 levels were higher in patients presenting with cachexia and low adiposity with implications in the pathogenic mechanisms and clinical consequences of GI cancer patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Tambaro, Imbimbo, Pace, Amabile, Rizzo, Orlando, Lauteri, Ramaccini, Catalano, Nigri, Muscaritoli and Molfino.)
Details
- Language :
- English
- ISSN :
- 2296-889X
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in molecular biosciences
- Publication Type :
- Academic Journal
- Accession number :
- 39144486
- Full Text :
- https://doi.org/10.3389/fmolb.2024.1449197